TPST-1120 Triplet Demonstrates Clinical Benefit in First-Line HCC
2023年10月11日 · TPST-1120, a PPAR⍺ antagonist, combined with atezolizumab and bevacizumab demonstrated superiority across multiple end points vs atezolizumab (Tecentriq) and bevacizumab (Avastin) for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), according to results from the planned data analysis of an ongoing global, randomized, phase 1b/2 study ...
First-in-human Phase I Trial of TPST-1120, an Inhibitor of
2024年4月18日 · TPST-1120 is a first-in-class oral inhibitor of PPARα, whose roles in metabolic and immune regulation are implicated in tumor proliferation/survival and inhibition of anticancer immunity. This first-in-human study of TPST-1120 alone and in combination with nivolumab supports proof-of-concept of PPAR …
PPAR⍺拮抗剂TPST-1120临床试验呈现积极结果 - 知乎
从随机分配到TPST-1120组的40名患者和分配到对照组的30名患者的数据，分别进行了9.2个月和9.9个月的 中位随访。 临床试验结果：
Pipeline | TPST-1120 | TPST-1495 | TREX-1 | Tempest Therapeutics
Tempest plans to advance amezalpat (TPST-1120) into a pivotal study in first-line HCC patients, as well as explore development beyond HCC given the signals observed in the Phase 1 study. Learn more TPST-1495 (dual EP2/ep4 antagonist) A first-in-class oral antagonist selective for two receptors in the prostaglandin (PGE2) pathway, EP2 and EP4.
PPARα Antagonism | TPST-1120 | Tempest Therapeutics
Amezalpat (TPST-1120) is a PPARα antagonist that has a dual mechanism of action to kill tumors, cells, both by targeting cancer cells dependent upon the FAO metabolic pathway directly and harnessing a patient’s immune system.
FDA 已授予 amezalpat (TPST-1120) 孤儿药资格 - 知乎
FDA 已授予 amezalpat (TPST-1120) 孤儿药资格，该药物是一种在研的 PPAR⍺ 拮抗剂，可用于治疗肝细胞癌 (HCC) 患者。 1b/2 期研究 (NCT04524871) 的数据支持这一认定，表明与阿替利珠单抗和贝伐单抗联合使用时，a…
TPST-1120 leads to intracellular metabolism shift from FAO to glycolysis TPST-1120 has an IC50 of 0.04 nM with > 35 fold selectivity over other PPAR isoforms Preclinical models shows eficacy of TPST-1120 as a single agent and in combination with an anti-PD1 antibody and chemotherapy
肝癌速递! 新药TPST-1120登场, 三联“豪华方案”实现客观缓解率提 …
TPST-1120联合治疗方案：肝癌患者ORR提升达74.4%！ 本次临床研究中，纳入临床的患者标准为年满18岁，并且患有未接受过全身治疗的肝细胞癌（即一线治疗）。
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, …
2024年4月18日 · TPST-1120 is a first-in-class oral inhibitor of peroxisome proliferator-activated receptor α (PPARα), a fatty acid ligand-activated transcription factor that regulates genes involved in fatty acid oxidation, angiogenesis, and inflammation, and is a novel target for cancer therapy. TPST-1120 displayed antitumor activity in xenograft models and synergistic tumor reduction in syngeneic tumor ...
Tempest大涨4000%：PPARα抑制剂一线肝癌1b/2期临床获积极数据
2023年10月12日 · 受此消息影响， Tempest Therapeutics 当天股价大涨3971%，目前市值为1.3亿美元。 TPST-1120为一款PPARα抑制剂，是 Tempest Therapeutics 的首发管线。 此次公开数据的一线肝癌联合治疗临床设计如下。 总结 Tempest Therapeutics 表示将与潜在合作伙伴讨论，推进TPST-1120的关键临床 ...